Literature DB >> 19703934

Functional characterization of cardiomyocytes derived from murine induced pluripotent stem cells in vitro.

Alexey Kuzmenkin1, Huamin Liang, Guoxing Xu, Kurt Pfannkuche, Hardy Eichhorn, Azra Fatima, Hongyan Luo, Tomo Saric, Marius Wernig, Rudolf Jaenisch, Juergen Hescheler.   

Abstract

Several types of terminally differentiated somatic cells can be reprogrammed into a pluripotent state by ectopic expression of Klf4, Oct3/4, Sox2, and c-Myc. Such induced pluripotent stem (iPS) cells have great potential to serve as an autologous source of cells for tissue repair. In the process of developing iPS-cell-based therapies, the major goal is to determine whether differentiated cells derived from iPS cells, such as cardiomyocytes (CMs), have the same functional properties as their physiological in vivo counterparts. Therefore, we differentiated murine iPS cells to CMs in vitro and characterized them by RT-PCR, immunocytochemistry, and electrophysiology. As key markers of cardiac lineages, transcripts for Nkx2.5, alphaMHC, Mlc2v, and cTnT could be identified. Immunocytochemical stainings revealed the presence of organized sarcomeric actinin but the absence of mature atrial natriuretic factor. We examined characteristics and developmental changes of action potentials, as well as functional hormonal regulation and sensitivity to channel blockers. In addition, we determined expression patterns and functionality of cardiac-specific voltage-gated Na+, Ca2+, and K+ channels at early and late differentiation stages and compared them with CMs derived from murine embryonic stem cells (ESCs) as well as with fetal CMs. We conclude that iPS cells give rise to functional CMs in vitro, with established hormonal regulation pathways and functionally expressed cardiac ion channels; CMs generated from iPS cells have a ventricular phenotype; and cardiac development of iPS cells is delayed compared with maturation of native fetal CMs and of ESC-derived CMs. This difference may reflect the incomplete reprogramming of iPS cells and should be critically considered in further studies to clarify the suitability of the iPS model for regenerative medicine of heart disorders.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19703934     DOI: 10.1096/fj.08-128546

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  54 in total

1.  Ascorbic acid enhances the cardiac differentiation of induced pluripotent stem cells through promoting the proliferation of cardiac progenitor cells.

Authors:  Nan Cao; Zumei Liu; Zhongyan Chen; Jia Wang; Taotao Chen; Xiaoyang Zhao; Yu Ma; Lianju Qin; Jiuhong Kang; Bin Wei; Liu Wang; Ying Jin; Huang-Tian Yang
Journal:  Cell Res       Date:  2011-12-06       Impact factor: 25.617

Review 2.  Stem cell therapy for ischemic heart disease.

Authors:  Mohammad Nurulqadr Jameel; Jianyi Zhang
Journal:  Antioxid Redox Signal       Date:  2010-10-28       Impact factor: 8.401

Review 3.  De novo myocardial regeneration: advances and pitfalls.

Authors:  Khawaja Husnain Haider; Stephanie Buccini; Rafeeq P H Ahmed; Muhammad Ashraf
Journal:  Antioxid Redox Signal       Date:  2010-10-12       Impact factor: 8.401

Review 4.  The 22q11.2 microdeletion: fifteen years of insights into the genetic and neural complexity of psychiatric disorders.

Authors:  Liam J Drew; Gregg W Crabtree; Sander Markx; Kimberly L Stark; Florence Chaverneff; Bin Xu; Jun Mukai; Karine Fenelon; Pei-Ken Hsu; Joseph A Gogos; Maria Karayiorgou
Journal:  Int J Dev Neurosci       Date:  2010-10-08       Impact factor: 2.457

5.  Forever young: induced pluripotent stem cells as models of inherited arrhythmias.

Authors:  David S Park; Glenn I Fishman
Journal:  Circulation       Date:  2012-05-30       Impact factor: 29.690

6.  Action Potential Shape Is a Crucial Measure of Cell Type of Stem Cell-Derived Cardiocytes.

Authors:  Glenna C L Bett; Aaron D Kaplan; Randall L Rasmusson
Journal:  Biophys J       Date:  2016-01-05       Impact factor: 4.033

7.  Conversion of mouse fibroblasts into cardiomyocytes using a direct reprogramming strategy.

Authors:  Jem A Efe; Simon Hilcove; Janghwan Kim; Hongyan Zhou; Kunfu Ouyang; Gang Wang; Ju Chen; Sheng Ding
Journal:  Nat Cell Biol       Date:  2011-01-30       Impact factor: 28.824

Review 8.  Therapeutic opportunities: telomere maintenance in inducible pluripotent stem cells.

Authors:  Francoise A Gourronc; Aloysius J Klingelhutz
Journal:  Mutat Res       Date:  2011-05-13       Impact factor: 2.433

9.  Small molecules enable cardiac reprogramming of mouse fibroblasts with a single factor, Oct4.

Authors:  Haixia Wang; Nan Cao; C Ian Spencer; Baoming Nie; Tianhua Ma; Tao Xu; Yu Zhang; Xiaojing Wang; Deepak Srivastava; Sheng Ding
Journal:  Cell Rep       Date:  2014-02-20       Impact factor: 9.423

Review 10.  Technical challenges in using human induced pluripotent stem cells to model disease.

Authors:  Krishanu Saha; Rudolf Jaenisch
Journal:  Cell Stem Cell       Date:  2009-12-04       Impact factor: 24.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.